As the DSS for carboplatin/pemetrexed was 25.5, and 0 for Osimertinib, this suggests that although the tumor had an EGFR mutation, the combined treatment with carboplatin and pemetrexed may have been sufficient, and the TKI-targeted treatment with osimertinib did not account for the clinical benefit. Here, EGFR is linked to neoplasm.